Wealthy investors expected to drive $32 trillion alternatives boom

Wealthy investors expected to drive  trillion alternatives boom


Shironosov | Istock | Getty Images

A version of this article appeared in CNBC’s Inside Alts newsletter, a guide to the fast-growing world of alternative investments, from private equity and private credit to hedge funds and venture capital. Sign up to receive future editions, straight to your inbox.

Investments in alternatives are expected to top $32 trillion by 2030, boosted in large part by growth from wealthy investors, according to a report from Preqin.

Total assets under management in alternatives – including private equity, hedge funds, real estate, venture capital, infrastructure, natural resources and private credit – are forecast to increase by 60% over the next five years, according to the private markets research firm.

A recovery in IPOs and mergers, falling interest rates and the AI boom will all drive a new growth cycle in private markets, according to the report. Assets in private credit are expected double to $4.5 trillion by 2030.

Yet even as deal activity and exits start to increase, fundraising from institutional investors continues to fall due to a lack of distributions and poor performance in many funds. Total fundraising for private equity plunged from a peak of $676 billion in 2023 to under $500 billion this year, the report said.

Get Inside Alts directly to your inbox

To power the next growth wave, the private equity industry is betting on wealthy investors. The report said ultra-high-net-worth individuals (typically defined as investors with $30 million or more), family offices and private-wealth managers will account for at least 30% to 40% of flagship fund capital “in future cycles.”

“With institutional rebalancing, private wealth can act as an alternative source of capital,” the report said. “Many larger managers are anticipating a doubling of private wealth capital raised in the short term. “

The big question is whether family offices and the ultra-wealthy are also following institutional investors out the door.

Family office allocations to private equity fell from 26% of their portfolios in 2023 to 23% in 2025, according to a Goldman Sachs survey of family offices. At the same time, family offices increased their allocation to public stocks.

Family offices are also focusing more on direct investments, bypassing funds and buying stakes in companies directly, according to surveys.

 With deal activity returning, some surveys suggest family offices and ultra-wealthy investors are planning to start investing more. A survey from BNY Wealth showed that 55% of family offices surveyed plan to increase their allocation to private equity funds in the next 12 months – the highest of any asset class.



Source

Walmart reports strong holiday growth, but earnings outlook falls short of estimates
Business

Walmart reports strong holiday growth, but earnings outlook falls short of estimates

Walmart said on Thursday that holiday-quarter sales rose nearly 6% and its quarterly earnings and revenue surpassed Wall Street’s expectations as gains in e-commerce, advertising and its third-party marketplace boosted its business. For the full current fiscal year, Walmart said it expects net sales to increase by 3.5% to 4.5% and adjusted earnings per share […]

Read More
Wayfair posts first annual sales gain since 2020, outperforms overall furniture market
Business

Wayfair posts first annual sales gain since 2020, outperforms overall furniture market

Wayfair store in Wilmette, Illinois. Courtesy: Wayfair Wayfair‘s annual sales grew last year for the first time since 2020 as the online furniture company continues to win over value-seeking consumers, the retailer announced Thursday.  In 2025, Wayfair revenue grew 5.1% to $12.5 billion. The gains follow a more than 1% year-over-year decline in 2024. The […]

Read More
FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals
Business

FDA chief warns U.S. is losing ground to China in early drug development, calls for faster trial approvals

Food and Drug Administration Commissioner Marty Makary warned that the U.S. is falling behind China in early-stage drug development and called for reforms that could streamline the process for starting trials on new treatments.  In an interview with CNBC on Wednesday, Makary specifically pointed to three bottlenecks that he said cause the U.S. to fall […]

Read More